Bind declines on mixed lung cancer results
This article was originally published in Scrip
Bind Therapeutics saw its stock price fall 20.4% to $8.40 per share on 19 November after results from the company's first-ever clinical trial showed low response rates and survival for lead drug candidate BIND-014 in non-small cell lung cancer (NSCLC) with slightly higher responses and longer survival in certain hard-to-treat populations.
You may also be interested in...
Oncology R&D head Axel Hoos spoke with Scrip about data at ASCO and the company’s strategy in immuno-oncology, cancer epigenetics, cell and gene therapy and synthetic lethality.
Private Company Edition: Arvelle, insitro, AbCellera and the University of Michigan have something in common – they each attracted more than $100m in venture capital investment.
Public Company Edition: After an initial hit to valuations from COVID-19, massive amounts of money have been raised by drug developers, such as argenx with a $862.5m stock sale. However, only two IPOs launched in the US in May, including ADC with a $267m offering.